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Jim Watson
Cold Spring Harbor Laboratory, Cold Spring Harbor, New York, NY 11724, USA1. Summary
The vast majority of all agents used to directly kill cancer cells (ionizing radiation,
most chemotherapeutic agents and some targeted therapies) work through either
directly or indirectly generating reactive oxygen species that block key steps in the
cell cycle. As mesenchymal cancers evolve from their epithelial cell progenitors,
they almost inevitably possess much-heightened amounts of antioxidants
that effectively block otherwise highly effective oxidant therapies. Also key to
better understanding is why and how the anti-diabetic drug metformin (the
world’s most prescribed pharmaceutical product) preferentially kills oxidant-
deficient mesenchymal p532 2cells. A much faster timetable should be adopted
towards developing more new drugs effective against p532 2 cancers.
Although the mortality from many cancers, particularly those of haemato-
poietic cells, has been steadily falling, the more important statistic may be
that so many epithelial cancers (carcinomas) and effectively all mesenchymal
cancers (sarcomas) remain largely incurable. Even though an increasing variety
of intelligently designed, gene-targeted drugs now are in clinical use, they gen-
erally only temporarily hold back the fatal ravages of major cancers such as
those of the lung, colon and breast that have become metastatic and gone
beyond the reach of the skilled surgeon or radiotherapist. Even though we
will soon have comprehensive views of how most cancers arise and function
at the genetic and biochemical level, their ‘curing’ seems now to many seasoned
scientists an even more daunting objective than when the ‘War on Cancer’ was
started by President Nixon in December 1971.
Propelling me then, 40 years ago, to turn the Cold Spring Harbor Laboratory
into amajor site for unravelling the genetic underpinnings of cancerwas the belief
that once the gene-induced molecular pathways to cancer became known, med-
icinal chemists would go on to develop much more effective gene-targeted
drugs. Unlike most early proponents of the ‘War on Cancer’, who thought that
DNA-damaging chemotherapeutic agents would bring real victories in one to
two decades, I thought three if not four more decades of focused research
would need to pass before wewould be in a position to go all out for total victory
[1]. In fact, only after the 1988–2003 Human Genome Project provided the world
with the highly accurate sequences for three billion human DNA letters has it
been possible to begin to approach the true genetic complexity of cancer.2. Molecular pathways to cancer as revealed through
DNA sequencing
By nowwe know that mutations in at least several hundred human genes (out of a
total of 21 000 genes) become serious ‘drivers’ of the abnormal cell growth and div-
ision process that generates human cancer [2]. They do so because they encode the
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enable external signals (growth factors) to move from the cell
surface receptors to key promoter–enhancer regions along the
24 human chromosomes. There they turn up the expression of
genes needed for cell growth and division aswell as the evasion
of programmed cell death, the latter of which much underlies
the ever-growing resistance of late-stage aggressive cancer
cells to radio- and chemotherapeutic therapies. Most impor-
tantly, there exist multiple molecular pathways that bring
about cell growth and proliferation, eachwith their own specific
surface receptors, cytoplasmic transducers, and promoters and
enhancers of gene expression [3].
Much potential cross talk exists between these pathways,
allowing new DNA mutations to create new pathways to
cancer when pre-existing ones are blocked. Already we know
that the emergence of resistance to the gene BRAF-targeted
anti-melanoma drug Zelboraf frequently results from driver
pathway cross talk, as does resistance to the targeted drugs
Iressa and Tarceva when they are deployed against EGFR-
driven lung cancers. Given the seemingly almost intrinsic
genetic instability of many late-stage cancers, we should not be
surprised when key old timers in cancer genetics doubt being
able to truly cure most victims of widespread metastatic cancer.
Resistance to gene-targeted anti-cancer drugs also comes
about as a consequence of the radical changes in underlying
patterns of gene expression that accompany the epithelial-
to-mesenchymal cell transitions (EMTs) that cancer cells undergo
when their surrounding environments become hypoxic [4].
EMTs generate free-floating mesenchymal cells whose flexible
shapes and still high ATP-generating potential give them the
capacity for amoeboid cell-likemovements that let themmetasta-
size to other body locations (brain, liver, lungs). Only when they
have so moved do most cancers become truly life-threatening.3. Epithelial-to-mesenchymal transitions
are a consequence of changes in
transcriptional regulation
EMTs leave intact the pre-existing order of DNA bases while
changing the way they are read into RNA transcripts. Under-
lying transcriptional regulation are site-specific DNA-binding
proteins, and sometimes regulatory RNAs, that recruit to
genes themachinery required to read those genes. This includes
the general transcription machinery and also enzymes that
modify the histones around which chromosomal DNA is
wound, and the DNA itself. These enzymes mediate methyl-
ation and acetylation of histones, as well as remodelling of the
nucleosomes in various ways, and methylation of DNA bases,
changes that can influence howa given gene is expressed. Regu-
lation of transcription extends far beyond its role in influencing
how cancer cells respond to changes in their environmental
surroundings. This regulation underlies all the multiple
switches that accompany the transition of fertilized eggs into
the differentiated cells (lung, kidney, etc.) of mature organisms.4. IL6-like cytokines drive mesenchymal
cells to commence cell proliferation
Much holding back the creation of effective drugs against
mesenchymal cancer cells has long been ignorance of theexternally driven signalling pathways propelling them into
stem cell growth and subsequent differentiation. Most atten-
tion until now has been focused on the Wnt signalling
pathway that sends b-catenin into the cell nucleus to activate
the TCF transcription factor for essential roles in EMTs as
well as stem cell functioning [5,6]. An even more important
villain may have been virtually staring in our faces for
almost two decades—one or more of the cytokine mediators
of inflammation and immunity, in particular, the IL6 interleu-
kin. IL6 blood serum levels, for example, steadily go up as
incurable cancers become more life-threatening [7,8]. Auto-
crine loops probably exist where cytokine binding to their
respective cell surface receptors sets into motion downstream
gene-activating pathways that not only generate more IL6
molecules but give their respective cancer cells an aura of
almost true immortality by blocking the major pathway to
programmed cell death (apoptosis). Pushing by cytokines of
otherwise quiescent mesenchymal cancer cells to grow and divide
probably explains why anti-inflammatory agents such as aspirin
lead to much less cancer in those human beings who regularly
take them [9].
Unfortunately, the inherently very large number of pro-
teins whose expression goes either up or down as the
mesenchymal cancer cells move out of quiescent states into
the cell cycle makes it still very tricky to know, beyond the
cytokines, what other driver proteins to focus on for drug
development. Ideally, we should largely focus first on finding
inhibitors of cancer cell proliferation as opposed to inhibitors of
cancer cell growth. Inhibiting, say, the synthesis of cellularmol-
ecular building blockswill slow down not only themetabolism
of cancer cells but also that of our body’s normally functioning
cells. By contrast, blocking proteins specifically moving
through the cell cycle should leave untouched the normal func-
tioning of the vast majority of our body’s cells and so generate
much less unwanted side effects.5. The gene transcription activator
Myc allows cells to move through
the cell cycle
Long thought to be a key, if not the key, protein against which
to develop cell-proliferation-inhibiting drugs is the powerful
gene transcription activator Myc. First known for its role in
driving cancers of blood-forming lymphocytes (e.g. Burkitt’s
lymphoma), Myc now also has been found to be a key driver
of the rapidly fatal ‘small cell’ lung cancers as well as the
likely driver of many late-stage incurable cancers, including
receptor negative and ductal breast cancers. Lots of Myc may
turn out to be an essential feature of much of the truly incurable
cancer. It simultaneously turns up the synthesis of the more
than 1000 different proteins required to move all cells through
the cell cycle. Although precisely how this almost 400-amino
acid long polypeptide works at the molecular level remains to
be worked out, it seems to play a unique role that cannot be
handled by any other class of transcription factors. Unlike our
first hunch that Myc was somehow an on–off specifier of
gene activity, it is a nonlinear amplifier of expression acting
universally on active genes except for the immediate early
genes that become expressed before Myc [10,11]. Already
many serious efforts have been made to develop drugs that
rsob.royalsocietypublishing.org
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nately, all such direct efforts have so far failed.
Using a dominant negative plasmid that blocks all Myc
functions, Gerard Evans’ laboratory, first at UCSF and now
in Cambridge, UK, has used mouse xenograph models of sev-
eral major human cancers to show Myc’s indispensable role in
moving through the cell cycle [12]. Although mouse stem cells
in Myc’s absence stop growing and dividing, they resume
normal functioning when Myc is turned back on. By contrast,
the turning off of Myc in human cancer cells preferentially
drives them into programmed cell death (apoptosis) with
one important exception: pancreatic adenocarcinoma cells do
not enter into apoptosis, quite possibly explaining why pan-
creatic cancer is so resistant to virtually all cell-killing
reagents (G. Evans 2012, personal communication).1201446. Bromodomain 4 proteins play essential
roles in maintaining the Myc levels
necessary for leukaemic cell growth
and division
An unanticipated powerful way for lowering Myc levels in
haematopoietic cancers has emerged from the discovery that
the incurable nature of MLL-AF9 acute myeloid leukaemia
(AML) depends upon the presence of the not yet well under-
stood protein bromodomain 4 (BRD4). When JQ1, developed
last year to treat the BRD4-driven rareNUTmidline carcinoma,
was used on humanMLL-AF9AML cells, they rapidly stopped
multiplying and differentiated into macrophages [13,14]. At
the same time, Myc levels rapidly plunged. Most importantly,
JQ1 does not block the normal macrophage production,
suggesting that Myc levels in macrophage-forming stem cells
do not depend upon BRD4. Their formation must depend on
a different chromosomal remodeller.7. Myc is turned on through multiple
molecular pathways
How Myc is turned on not only in other cancers but also
during normal human development remains largely to be
worked out. Likewise not known is how the BRD4 protein
at the molecular level helps turn on Myc synthesis in MLL-
AF9-driven leukaemia. Until JQ1 goes into the clinic against
leukaemia late this year, we will not moreover know for
sure whether resistance to JQ1 will compromise its clinical
utility. Unfortunately, the answer is probably yes because
artificially turning up Myc by means that bypass BRD4
causes JQ1 resistance. Moreover, there are already known
multiple ways to turn on Myc expression in normal cells,
each starting by signals binding to specific cell surface recep-
tors then moving through one or more layers of signal
transducers to the nucleus to turn up the transcription of
genes needed for cell growth and division. Myc synthesis is
not only downstream of the cytokine Jak–Stat3 signal trans-
duction pathway but also downstream of the HER2–RAS–
RAF–SHp2–ERK3 pathway that helps drive the growth of
much, if not most, breast cancer [15]. Whether they in turn
feed into BRD protein-dependent gene-activating pathways
remains for the future to reveal. A multiplicity of Myc-inhibit-
ing specific drugs may have to be in our arsenal before wecan routinely move beyond delaying death from incurable
cancers to true lifetime long cures.8. Detecting key cancer cell vulnerabilities
through RNAi screens
That the BRD4 protein is among the major Achilles’ heels of
incurable AML became known not because of a chance obser-
vation but by using a powerful newmethodology for detecting
molecular weaknesses that are cancer cell-specific. At its heart
has been the deployment over the past several years by Greg
Hannon at Cold Spring Harbor Laboratory of short hairpin
RNA molecules (shRNAs) specifically designed to knock
back the functioning of single human genes [16]. A genome
shRNA library containing multiple probes (four to six) for
each human gene possesses some 100 000 shRNAs. Testing
all of them extensively against just one type of cancer still
poses a formidable, logistical challenge likely to require 1- to
2-year long intervals for even ‘big science laboratories’.
Much smaller highly focused libraries, however, now
can be deployed by high-quality, university-level science
laboratories provided there already exist hints as to what
molecular vulnerabilities might be found. Forearmed by
knowledge that invariably incurable forms of acute myeloblas-
tic leukaemia (AML) originate from rearrangements of a key
gene involved in epigenetic chromosomal remodelling, Chris
Vakoc and Johannes Zuber at the Cold Spring Harbor Labora-
tory found the gene-activating BRD4 as the most pronounced
potential molecular weakness of an MLL-AF9 human AML.
They did so by screening libraries of only some 1000 probes
designed to knockout 234 genes coding for the key proteins
involved in epigenetic-driven gene expression.
Most recently, Vakoc has found three other major protein
players (Menin, Ezh1/2 and Eed) that work together with
BRD4 tomakeMLL-AF9AML incurable by currently deployed
anti-cancer drugs [17]. Drugs inhibiting their respective func-
tioning should also provide effective anti-AML agents. Ezh1/2
and Eed code for polycomb proteins that block specific gene
expression, whereas the Menin gene, like the BRD4 gene, acti-
vates gene expression. Loss of functional Ezh1/2 and Eed
blocks the expression of the CdKn2a gene-encoded p16 and
p19 proteins that have widespread cell-cycle-progression-block-
ing roles. The Menin protein’s molecular role probably involves
its already known binding to MLL. Like BRD4, it may have a
Myc-level-raising role. Finding out how such chromosome
remodelling dependencies emerge and evolve during tumour
progression will directly impact the clinical implementation of
epigenetic-based anti-cancer therapies.9. BRD4 functioning is vital not only for
fast-growing leukaemias but also for
many, if not most, dangerous
lymphomas and myelomas
As soon as possible, we must find out in more detail how far
the drug JQ1’s anti-cancer actions extend beyond MLL-AF9-
specific AMLs. Already we know that in mice it stops equally
well the more curable, non-MLL rearranged strains of AML as
well as all forms of acute lymphocytic leukaemia (ALL).
BRD4’s capacity to heighten Myc levels thus probably
rsob.royalsocietypublishing.org
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proteins of ALL, like those of AML, also turn off the cell-
cycle-inhibiting CdKn2a-coded proteins p16 and p19 remains
to be seen. JQ1 also stops the growth in mice of many fast-
growing B-, and T-cell lymphomas, suggesting that their
untreated BRD4 protein maintains their high Myc levels
necessary to make them fatal. In JQ1-resistant lymphomas
(e.g. Jurkat cell), Myc synthesis must be turned on by a differ-
ent route. Cell lines from most human multiple myeloma
victims also frequently show high sensitivity to JQ1 [18].
There, the twosome cocktail of JQ1 and the now widely
deployed proteasome inhibitor Velcade reinforce each other’s
anti-myeloma actions. When JQ1 becomes broadly available
clinically, hopefully bymid-2013, it may considerably lengthen
the 3–5 more years of additional life provided to most
myeloma victims by Velcade administration.
JQ1 also significantly slows down the growth of a small
but real number of cell lines derived from many major
solid cancers (e.g. prostate and melanoma). BRD4 may have
been only called into play late as these cancers evolve to
become more aggressive. Of more importance is JQ1’s failure
to stop the growth of the vast majority of solid tumour cell
lines. The heightened Myc levels needed by, say, cancers of
the prostate and breast may instead be provided by the inter-
vention of one or more of the some 35 other BRD proteins or
other chromatin regulators. Unfortunately, we do not yet
know how the vast majority of them function beyond the
fact that their BRD pockets, by binding to the acetyl groups,
help turn on, not turn off, gene activation. JQ1’s unanticipated
blocking of sperm functioning most excitingly has led to the
recent discovery of a testis-specific bromodomain (BRDT)
essential for chromatin remodelling during spermatogenesis.
Occupancy of the BRDT acetyl-lysine pocket by JQ1 generates
a complete and reversible contraceptive effect [19]. Early evi-
dence suggests that BRDT does not promote Myc synthesis.
There may be out there soon to be found, say, breast-specific
or prostate-specific BRD gene activators. Most important to
learn is whether they also do or do not drive Myc synthesis.10. The circadian rhythm regulator
(PER2) by negatively regulating
Myc levels functions as an important
tumour suppressor
Myc’s paramount role in moving cancer cells through the cell
cycle has recently been reinforced by two highly independent
RNAi screens to find genes whose loss of function selectively
kills cancer cells [20,21]. In sampling largely different sets of
genes, they both honed in on the gene CSNKe coding for
protein kinase casein kinase 2 epsilon. Among its many
multiple targets for phosphorylation and subsequent proteo-
some-mediated degradation is the transcription factor PER2
gene whose selective binding to DNA turns off the function
of many genes including Myc. Already long known has been
PERIOD 2 (PER2) involvement as a clock protein at the heart
of the circadian rhythms of higher animal cells. Later, quite
unexpectedly, PER2 was found to function as a tumour sup-
pressor, with the absence of both its copies causing the rate of
radiation-induced cancers to rise. It now seems obvious that
its anti-cancer action arises from its ability to turn off Myc. In
PER2’s absence, Myc levels greatly rise, thereby explainingwhy tumours of many types all display higher levels of
CSNKe than found in their normal cell equivalents. Common
sense suggests that specific CSNKe inhibitors should soon be
broadly tested against a large variety of human cancers.11. High-Myc-driven, fast proliferating cells
possess cell cycle vulnerabilities
High-Myc-level proliferating cells less efficiently proceed
through the mitotic cycle than cells driven by lower Myc
levels. Why high Myc leads to many more mitotic-generated
chromosome abnormalities has recently been explained
through a large RNAi screen designed to reveal ‘synthetic
lethal’ genes that only have vital function under conditions
of high Myc. Most unexpectedly, they pinpointed key roles
for the SUMO-activating genes SAE1 and SAE2 involved in
proteasome-specific protein degradation [22]. When they
are blocked from functioning, large numbers of Myc-driven
genes somehow become switched from on to off. As expected,
many function in the formation and breakdown of the mitotic
spindle. A much less anticipated second class functions in
ubiquitin-based, proteasome-mediated protein degradation.
Conceivably, the fast growth rates of high-Myc-level-driven
proliferating cells generate more mitosis-involved proteins
than their respective proteasomes can timely breakdown.
In any case, drugs designed to block SAE1 and SAE2 should
preferentially kill fast-proliferating cancer cells.
High-Myc-level vulnerability is also generated by subopti-
mal supplies of CD kinase 1 (CDK1) that functions with the A
type cyclins during the late S phase of the cell cycle. As long as
theMyc levels are those of normal cells, proliferating cells have
sufficient CDK1. But whenmoreMyc leads to faster cell cycles,
much more CDK1 is required to prevent failed cell divisions.
So, it makes a prime candidate for the development of an
effective drug against high-Myc-driven cancers [23].12. Selectively killing cancer cells through
exploiting cancer-specific metabolic
and oxidative weaknesses
We must focus much, much more on the wide range of meta-
bolic and oxidative vulnerabilities that arise as consequences
of the uncontrolled growth and proliferation capacities of
cancer cells. As human cancers become driven to more
aggressive glycolytic states, their ever-increasing metabolic
stress makes them especially vulnerable to sudden lowering
of their vital ATP energy supplies. 3-Bromopyruvate, the
powerful dual inhibitor of hexokinase as well as oxidative
phosphorylation, kills highly dangerous hepatocellular carci-
noma cells more than 10 times faster than the more resilient
normal liver cells and so has the capacity to truly cure, at
least in rats, an otherwise highly incurable cancer [24,25].
The structurally very different hexokinase inhibitor 2-deoxy-
glucose, through its ability to block glycolysis, also has the
potential for being an important anti-cancer drug. Not surpri-
singly, it works even better when combined with inhibitors
of ATP-generating oxidative phosphorylation such as the
mitochondrial target drug Mito Q [26].
A key mediator of cellular response to falling ATP levels
is the AMP-dependent protein kinase AMPK, which in
rsob.royalsocietypublishing.org
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to push metabolism away from anabolic growth patterns [27].
By inhibiting mTOR it slows protein synthesis, and by phos-
phorylating acetyl-CoA carboxylase it slows down lipid
synthesis. The glycolytic pathways that produce the cellular
building blocks are indirectly controlled by AMPK through
its phosphorylation of the p53 transcription factor. Activated
p53 slows down glycolysis during cell cycle arrest through
turning on its TIGAR gene target. Its respective protein
breaks down the key regulator of glycolysis fructose 2,6-
bisphosphate as well as blocking further cell cycles through
turning on the p21 gene.en
Biol3:12014413. Preferential cancer cell killing by
apoptosis reflects high p53 levels
The enhanced apoptosis capability of early-stage epithelial
cancer cells, in comparison with their normal cell equivalents,
reflects their higher content of activated p53 transcription
factor. Overexpression and amplification of the p53 repres-
sors MDM2 and MDM4 are common across cancer types.
In the case of melanomas, p53 function is commonly shut
down by overexpression of MDM4. Already a drug exists
that through its inhibition of MDM4 makes melanoma
much more treatable [28]. Knowing more about why p53 acti-
vation sometimes leads to cell cycle arrest (senescence) and
under different circumstances results in apoptosis remains
an important challenge for the immediate future.14. P53 induces apoptosis by turning on
the synthesis of genes whose primary
function is the synthesis of reactive
oxygen species
How p53 turns on apoptosis was first revealed through
elegant gene expression studies carried out in Bert Vogel-
stein’s Johns Hopkins laboratory in 1997 [29]. Although
looking for genes expressed only during apoptosis, they dis-
covered a set of 13 p53-induced genes (PIG genes), each of
which are likely key players in the cellular synthesis of reac-
tive oxygen species (ROS; H2O2 hydrogen peroxide, the OH
2
radiation and O2
2 superoxides). PIG3, for example, codes for a
quinone oxidoreductase that is a potent generator of ROS
[30,31]. p53 target genes also play major roles in downstream
processes through turning on synthesis of some 10 different
mitochondrial functioning proteins such as BAX, PUMA
and NOXA, as well as death receptors such as DR4 and
DR5, that in ways yet to be elucidated help carry out the
many successive proteolysis stages in apoptosis [32].
Equally important, p53 turns on the synthesis of the
key proteins involved in the apoptotic (programmed cell
death) elimination of cells that have no long-term future,
say, through unsustainable metabolic stress or damage
to cellular chromosomes brought about by exposure to
ultraviolet or ionizing radiation. So, removing such cells are
complex sets of largely mitochondrial-sited degradation
events. As the successive stages in apoptosis unravel,
the respective dying cells lose mitochondrial functioning
and release cytochrome c, culminating in DNA-liberating
cell dissolution.15. Leakage from drug-impaired
mitochondrial electron transport chains
raises reactive oxygen species levels
Themitochondrial electron transport generationofATPandheat
is obligatorily accompanied by the production of ROS (such as
theOH2 radical,H2O2 andO2
2 superoxides).Normally, prevent-
ing ROS molecules from irreversibly damaging key nucleic acid
and protein molecules are potent antioxidative molecules such
as glutathione and thioredoxin [33]. When present in normal
amounts, they cannot handle the much larger amount of ROS
generated when oxidative phosphorylation becomes inhibited
by mitochondrial-specific drugs such as rotenone that block
feeding ofNADH into the respiratory chain or by 30-30 diindolyl-
methane (DIM), the active component in the long-reputed
chemo-preventative Brassica vegetables, which inhibits themito-
chondrial F1F0 ATP synthesis complex [34]. Still-remaining ROS
molecules through oxidizing intra-mitochondrial targets induce
the apoptotic elimination of cells damaged from excessive oxi-
dative stress. Already, DIM is used as an adjuvant therapy for
recurrent respiratory papillomatosis in humans. The molecular
mechanism(s) throughwhich ROS induce apoptosis remains to
be found—hopefully soon. Now,wewill be surprised if they do
not somehowdirectly oxidize and so activate one ormore of the
BAX-like proteins involved in p53-mediated apoptosis.
That ROSby themselves canmediate apoptosiswas recently
convincingly shown by the finding that the ‘first-in-class’ anti-
cancer mitochondrial drug elesclomol (discovered by Synta
Pharmaceuticals through screening for anti-apoptotic agents)
kills cancer cells through promoting ROS generation [35].
When these resulting ROS molecules are destroyed through
the simultaneous administration of the antioxidant molecule
N-acetylcysteine, preferential killing of cancer cells stops. The
failure of elesclomol to generate apoptosis in non-cancerous
cells probably arises from the inherently lower ROS level gener-
ated by normal mitochondrial electron transport machinery.16. Reactive oxygen species may directly
induce most apoptosis
That elesclomol promotes apoptosis through ROS generation
raises the question whether much more, if not most, program-
med cell death caused by anti-cancer therapies is also ROS-
induced. Long puzzling has been why the highly oxygen
sensitive ‘hypoxia-inducible transcription factor’ HIF1a is inac-
tivated by both the, until now thought very differently acting,
‘microtubule binding’ anti-cancer taxanes such as paclitaxel
and the anti-cancer DNA intercalating topoisomerases such as
topotecan or doxorubicin, as well as by frame-shifting muta-
gens such as acriflavine [36,37]. All these seemingly unrelated
facts finally make sense by postulating that not only does ioniz-
ing radiation produce apoptosis through ROS but also today’s
most effective anti-cancer chemotherapeutic agents as well as
the most efficient frame-shifting mutagens induce apoptosis
through generating the synthesis of ROS [38–40]. That the
taxane paclitaxel generates ROS through its binding to DNA
becameknown fromexperiments showing that its relative effec-
tiveness against cancer cell lines ofwidely different sensitivity is
inversely correlated with their respective antioxidant capacity
[41,42]. A common ROS-mediated way through which almost
rsob.royalsocietypublishing.org
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that become resistant to chemotherapeutic control become
equally resistant to ionizing radiotherapy.
Recent use of a 50 000 member chemical library at MIT’s
Koch Cancer Center to search out molecules that selectively
killed K-RAS-transformed human fibroblasts revealed the piper-
idine derivation lanperisone [43]. ROS generation underlies its
cancer cell killing action. Surprisingly, this already clinically
used muscle relaxant induced non-apoptotic cell death in a
p53 (þþ versus22) independent manner. When lanperisone
was applied in the presence of the ROS-destroying antioxidant
scavenger molecules deferoxamine, butylated hydroxylamine
or the antioxidant trolox, no activity was observed.Biol3:12014417. Blockage of reactive-oxygen-species-
driven apoptosis by antioxidants
Although we know ROS as a positive force for life through
their apoptosis-inducing role, for much longer we have
feared them for their ability to irreversibly damage key proteins
and nucleic acid molecules. So when not needed, they are con-
stantly being neutralized by antioxidative proteins such as
glutathione, superoxide dismutase, catalase and thioredoxin.
Controlling their synthesis as well as that of many more
minor antioxidants is the Nrf2 transcription factor, which prob-
ably came into existence soon after life as we know it started.
Most importantly, at Cancer Research UK in Cambridge,
David Tuveson’s laboratory has recently shown that Nrf2 syn-
thesis is somehow upregulated by the cell growth and
division-promoting RAS, RAF and MYC oncogenes [44]. Bio-
logically, this makes sense because we want antioxidants
present when DNA functions to make more of itself.
The fact that cancer cells largely driven by RAS and Myc
are among the most difficult to treat may thus often be due to
their high levels of ROS-destroying antioxidants. Whether
their high antioxidative level totally explains the effective incur-
ability of pancreatic cancer remains to be shown. The fact that
late-stage cancers frequently have multiple copies of RAS and
MYC oncogenes strongly hints that their general incurability
more than occasionally arises from high antioxidant levels.
Clearly important to learn is what other molecules exist that
turn on Nrf2 expression. During the yeast life cycle and prob-
ably that of most organisms, oxidative phosphorylation is
clearly separated by time from when DNA synthesis occurs.
Whether Nrf2 levels also go up and down during the cell
cycle remains important to be known soon.18. Enhancing apoptotic killing using
pre-existing drugs that lower
antioxidant levels
Already there exist experiments with haematopoietic cells in
which the cancer-cell-killing capacity of the ROS generator
arsenic trioxide (As2O3) has been shown to be inversely corre-
lated with the content levels of the major cellular antioxidant
glutathione [45]. As2O3 also knocks down the reductive power
of thioredoxin necessary for several key steps in cellular metab-
olism. Its capacity to inhibit both thioredoxin and glutathione
widens its potential for a successful deployment against many
major cancers beyond promyeloblastic leukaemia. Also capableof enhancing the cytotoxic effect of As2O3 is ascorbic acid,
which, though known for its antioxidant role in cells, is conver-
ted into its oxidizing formdehydroascorbic acid.Unfortunately,
up until now, we do not yet have clinically effective ways to
lowerglutathione levels. Lowering its level throughdeployment
of the drug buthionine sulphazine that blocks its synthesis leads
quickly to upregulation of the Nrf2 transcription factor that in
turn upregulates glutathione synthesis [46]. A more general
way to reduce antioxidant levels deploys motexafin gadoli-
nium, a member of a class of porphyrin molecules called
texaphyrins. Through a process called futile redox recycling, it
transfers hydrogen fromantioxidants to produce ROS.Unfortu-
nately, clinical trials designed to show its enhancement of
chemo- and radiotherapies have so far shown only modest life
extensions as opposed to cures.
Through selecting for compounds that preferentially
induce apoptosis in cancer cells as opposed to normal cells,
the natural product piperlongumine from the Piper longum
plant was recently revealed as a potential anti-cancer drug
[47]. Most exciting, it mediates its action through its binding
to the active sites of several key cellular antioxidants (e.g. glu-
tathione S transferase and carbonyl reductase 1) known to
participate in cellular responses to ROS-induced oxidative
stress. That piperlongumine failed to raise ROS levels in
non-cancerous cells probably resulted from their inherently
lower levels of these antioxidants which, in turn, result
from less activation of the Nrf2 transcription factor.19. Anti-angiogenic drugs work only when
used in conjunction with reactive
oxygen species generators
The non-toxic anti-angiogenesis protein endostatin (discovered
and promoted in the late 1990s in Judah Folkman’s Boston lab-
oratory and now resurrected by Yongzhang Luo in Beijing)
shows anti-cancer activity only when it is used together with
conventional chemotherapeutic agents. This fact, long puzzling
tome, may be due to the chemotherapeutic component provid-
ing the ROS needed for cancer cell killing [48]. By itself, the
hypoxia resulting from endostatin action may not be sufficient
for cancer cell killing. A similar explanation may explain why
Genentech’s avastin also only works when combined with che-
motherapy. By contrast, the killing of mutant BRAFmelanoma
cells by Zelboraf works very well in the absence of any obvious
direct source of ROS.Conceivably, themetabolic stress resulting
from its turning off the RAS–ERK pathways somehow shuts
down the Nrf2 pathways, letting ROS rise to the level needed
to kill the drug-weakened melanoma cells.20. Lower reactive oxygen species
levels in stem cells reflect higher
levels of antioxidants
For more than a decade, there has existed too long ignored
evidence that normal stem cells have lower ROS levels than
their differentiated progeny. Just a year ago, even more con-
vincing experimentation showed that breast cancer stem cells
also contain lower ROS levels than those found in their cancer-
ous epithelial-like progeny cells [49]. All stem cells, be they
normal or cancerous, probably have lower ROS levels as a
rsob.royalsocietypublishing.or
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idant molecules such as glutathione and thioredoxin. Most
likely, these heightened amounts have evolved to protect
chromosomal RNA from ROS-induced damage to the more
exposed region of chromosomal DNA as it undergoes changes
in compaction as it moves through the cell cycle. Whether all
dividing cells have higher antioxidant levels remains to be
worked out. If so, all stem cells will be inherently much
more resistant to ROS-induced apoptotic killing than more
differentiated, much less antioxidant-rich progeny cells.g
Open
Biol3:12014421. Metformin selectively targets (kills)
mesenchymal cancer stem cells
Already we have at our disposal a relatively non-toxic, exces-
sively well-tested drug that preferentially kills mesenchymal
stem cells. In a still much unappreciated article published
three years ago in Cancer Research, Kevin Struhl’s laboratory at
HarvardMedical School first showed that metformin, a blocker
of stage 2 oxidative phosphorylation, selectively targets stem
cells. When so applied with chemotherapeutic agents to block
xenographic tumour growth, it induces prolonged remission if
not real cures [50,51]. But when metformin was left out of
these experiments, subsequent multiplication of unkillable
mesenchymal stem cells lets these xenographs grow into life-
threatening forms, showing that chemotherapy by itself does
not kill stem cells. This most widely used anti-diabetic drug’s
heightened ability to kill late-stage mesenchymal cancer cells
probably explains why those humans who use it regularly
have reduced incidences of many cancers.
Metformin is presently being added to a number of anti-
cancer chemotherapeutic regimes to see whether it magnifies
their effectiveness in humans. The fact that metformin works
much more effectively against p532 2 cells suggests that it
may be most active against late-stage cancers, the vast
majority of whose cells have lost both of their p53 genes. By
contrast, the highly chemo-radio-sensitive early-stage cancers
against which most of anti-cancer drug development has
focused might very well show little metformin effectiveness.
By the end of 2013, we should know whether it radically
improves any current therapies now in use. Highly focused
new drug development should be initiated towards finding
compounds beyond metformin that selectively kill stem
cells. And the reason why metformin preferentially kills
p532 2 stem cells should be even more actively sought out.22. Free-radical-destroying antioxidative
nutritional supplements may have
caused more cancers than they have
prevented
For as long as I have been focused on the understanding
and curing of cancer (I taught a course on Cancer at Harvard
in the autumn of 1959), well-intentioned individuals have been
consuming antioxidative nutritional supplements as cancer pre-
ventatives if not actual therapies. The past, most prominent
scientific proponent of their valuewas the great Caltech chemist,
Linus Pauling, who near the end of his illustrious career wrote a
book with Ewan Cameron in 1979, Cancer and Vitamin C, about
vitamin C’s great potential as an anti-cancer agent [52]. At thetime of his death from prostate cancer in 1994, at the age of 93,
Linus was taking 12 g of vitamin C every day. In light of the
recent data strongly hinting that much of late-stage cancer’s
untreatability may arise from its possession of too many antiox-
idants, the time has come to seriously ask whether antioxidant
use much more likely causes than prevents cancer.
All in all, the by now vast number of nutritional interven-
tion trials using the antioxidants b-carotene, vitamin A,
vitamin C, vitamin E and selenium have shown no obvious
effectiveness in preventing gastrointestinal cancer nor in
lengthening mortality [53]. In fact, they seem to slightly
shorten the lives of those who take them. Future data may,
in fact, show that antioxidant use, particularly that of vitamin
E, leads to a small number of cancers that would not have
come into existence but for antioxidant supplementation.
Blueberries best be eaten because they taste good, not because
their consumption will lead to less cancer.23. A much faster timetable for developing
anti-metastatic drugs
The world of Physics already knew 20 years ago that it had no
choice but to go very big for the Higgs boson. To the civilized
world’s great relief, they now finally have it. Biology andMedi-
cine must likewise now again aim big—as when we first
promised the world in 1988 that the still to be found human
genome would later prove indispensable for the curing of
most cancers and so went for it big. If, however, we continue
to move forward at today’s never frantic, largely five-day
working week, the never receding 10–20 year away final vic-
tory that our cancer world now feels safe to project will
continue to sink the stomachs of informed cancer victims and
their families. That we now have no General of influence,
much less power, say an Eisenhower or even better a Patton,
leading our country’s War on Cancer says everything.
Needed soon is a leader that has our cancer drug development
world working every day and all through the night.
The now much-touted genome-based personal cancer
therapies may turn out to be much less important tools for
future medicine than the newspapers of today lead us to
hope [54]. Sending more government cancer monies towards
innovative, anti-metastatic drug development to appropriate
high-quality academic institutions would better use National
Cancer Institute’s (NCI) monies than the large sums spent
now testing drugs for which we have little hope of true break-
throughs. The biggest obstacle today to moving forward
effectively towards a true war against cancer may, in fact,
come from the inherently conservative nature of today’s
cancer research establishments. They still are too closely
wedded to moving forward with cocktails of drugs targeted
against the growth promoting molecules (such as HER2,
RAS, RAF, MEK, ERK, PI3K, AKT and mTOR) of signal
transduction pathways instead of against Myc molecules
that specifically promote the cell cycle.
Most needed now are many new anti-Myc drugs beyond
the exciting new BRD4 inhibitors, such as JQ1, as well as mul-
tiple drugs that inhibit the antioxidative molecules that likely
make, say, pancreatic cancer so incurable. They should much
enhance the effectiveness of all current radio- and chemothera-
peutic regimes. As such, they will likely cure many more now
incurable cancers. How they will interact as cocktail partners
with the newer targeted therapies that do not directly generate
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expanded search for drugs that prevent p53 breakdown.sob.royalsocietypublishing.org
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Biol3:12014424. A billion dollars should suffice to
identify all the remaining
proteins needed for curing most
metastatic cancer
The total sum of money required for RNAi methodologies to
reveal the remaining major molecular targets for future anti-
cancer drug development need not be more than 500–1000
million dollars. Unfortunately, the NCI now is unlikely to
take on still one more big science project when it is so
hard-pressed to fund currently funded cancer programmes.
Still dominating NCI’s big science budget is The Cancer
Genome Atlas (TCGA) project, which by its very nature
finds only cancer cell drivers as opposed to vulnerabilities
(synthetic lethals). While I initially supported TCGA getting
big monies, I no longer do so. Further 100 million dollar
annual injections so spent are not likely to produce the
truly breakthrough drugs that we now so desperately need.
Happily, the first RNAiwhole genome big screen backed by
a ‘big pharma’ firm has just started with Pfizer working with
the Cold Spring Harbor Laboratory. Even, however, if several
more giants working separately join in, collectively they willnaturally focus on major cancers such as those of the breast,
colon and lung. I doubt they will soon go big against, say,
either melanoma or oesophageal cancer. Greg Hannon here at
Cold SpringHarbor will probably be the first academic scientist
to come to grips with the non-trivial experimental challenges
provided by whole genome, 100 000 RNAi probe screens,
through both his collaboration with Pfizer and through using
monies separately provided by the Long Island-based Lustgar-
ten Foundation’s support for a comprehensive pancreatic
cancer target screen and by Hollywood’s ‘stand up against
cancer’ support for breast cancer drug target identification.
Although our enthusiasm for big RNAi screens remains far
from universally shared, lack of money should not now keep
us from soon seeing whether whole genome methodologies
live up to their much-touted expectations [55]. The Cold
Spring Harbor Laboratory happily has the means to move
forward almost as if it were in a true war.
Further financial backing, allowing many more cancer-
focused academic institutions to also go big using RNAi-based
target discovery as well as to let them go on to the early stages
of subsequent drug discovery, is not beyond the might of the
world’s major government research funding bodies nor that of
our world’s many, many super billionaires. The main factor
holding us back from overcoming most of metastatic cancer
over the next decade may soon no longer be lack of knowledge
but our world’s increasing failure to intelligently direct its ‘mon-
etarymight’ towardsmore human-society-benefiting directions.AUTHOR PROFILE
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